Nataliya V. Uboha - Concepedia

Author

Nataliya V. Uboha

University of Wisconsin Carbone Cancer Center ORCID

Also Known As

Chan, Nancy, N. Uboha, N.V. Uboha, Nataliya Uboha, Nataliya V Uboha, Nataliya V. Uboha, Nataliya Volodymyrivna Uboha, William S. Middleton Veterans Administration Health System, Madison, WI, USA

271

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

University of Wisconsin Carbone Cancer Center The University of Texas MD Anderson Cancer Center Yale University University of Wisconsin–Madison Dana-Farber Cancer Institute

About

Nataliya V. Uboha is an author at University of Wisconsin Carbone Cancer Center specializing in oncology, medicine, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	15	643
2	Health Sciences	4	4	115
3	Cell Biology	4	4	152
4	Cellular Physiology	2	2	99
5	Natural Sciences	1	1	31

Nataliya V. Uboha

Publications

904

Citations

H-Index

Page 1

	Year	Citations
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial Jonathan D. Schoenfeld, Anita Giobbie‐Hurder, Srinika Ranasinghe, The Lancet Oncology MedicinePrevious PdBronchial NeoplasmImmune Checkpoint InhibitorCancer Treatment	2022	225
Efficacy and Safety of Adagrasib plus Cetuximab in Patients with <i>KRAS</i> G12C-Mutated Metastatic Colorectal Cancer Rona Yaeger, Nataliya V. Uboha, Meredith S. Pelster, Cancer Discovery	2024	88
Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology Jaffer A. Ajani, Thomas A. D’Amico, David J. Bentrem, Journal of the National Comprehensive Cancer Network Cancer ManagementGastroenterologyPathologySurgeryBiomarker Testing	2025	72
A Calcium- and Calmodulin-Dependent Kinase Iα/Microtubule Affinity Regulating Kinase 2 Signaling Cascade Mediates Calcium-Dependent Neurite Outgrowth Nataliya V. Uboha, Marc Flajolet, Angus C. Nairn, Journal of Neuroscience Molecular RegulationSynaptic TransmissionCytoskeletonSynaptic SignalingCellular Physiology	2007	68
Phase II study of spartalizumab (PDR001) and LAG525 in advanced solid tumors and hematologic malignancies. Nataliya V. Uboha, Mohammed Milhem, Christina Kovacs, Journal of Clinical Oncology ImmunologyPathologyPhase Ii StudyImmunotherapeuticsImmunotherapy	2019	59
Implementation and Clinical Utility of an Integrated Academic-Community Regional Molecular Tumor Board Mark E. Burkard, Dustin A. Deming, Benjamin M. Parsons, JCO Precision Oncology	2017	38
CX-072 (pacmilimab), a Probody<b> <sup>®</sup> </b> PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study Aung Naing, Fiona Thistlethwaite, Elisabeth G.E. de Vries, Journal for ImmunoTherapy of Cancer	2021	35
Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer Howard S. Höchster, Nataliya V. Uboha, Wells A. Messersmith, Cancer Chemotherapy and Pharmacology MedicinePharmacologyColorectal CancerPathologyPhase Ii Study	2014	33
Cytoplasmic localization of calcium/calmodulin‐dependent protein kinase I‐α depends on a nuclear export signal in its regulatory domain Diann R. Stedman, Nataliya V. Uboha, Timothy T. Stedman, FEBS Letters Regulatory DomainMolecular RegulationMolecular BiologyCrm1 ComplexCellular Physiology	2004	31
Farnesoid X receptor mediates macrophage-intrinsic responses to suppress colitis-induced colon cancer progression Xingchen Dong, Ming Qi, Chunmiao Cai, JCI Insight DysbiosisImmunologyGastroenterologyPathologyFarnesoid X Receptor	2024	29

Page 1